Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
Publication
, Journal Article
Muir, AJ; Gong, L; Johnson, SG; Lee, MTM; Williams, MS; Klein, TE; Caudle, KE; Nelson, DR ...
Published in: Clin Pharmacol Ther
February 2014
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2014
Volume
95
Issue
2
Start / End Page
141 / 146
Location
United States
Related Subject Headings
- Treatment Outcome
- Ribavirin
- Recombinant Proteins
- Polymorphism, Single Nucleotide
- Polyethylene Glycols
- Pharmacology & Pharmacy
- Interleukins
- Interferons
- Interferon-alpha
- Interferon alpha-2
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Gong, L., Johnson, S. G., Lee, M. T. M., Williams, M. S., Klein, T. E., … Clinical Pharmacogenetics Implementation Consortium (CPIC), . (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther, 95(2), 141–146. https://doi.org/10.1038/clpt.2013.203
Muir, A. J., L. Gong, S. G. Johnson, M. T. M. Lee, M. S. Williams, T. E. Klein, K. E. Caudle, D. R. Nelson, and D. R. Clinical Pharmacogenetics Implementation Consortium (CPIC). “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.” Clin Pharmacol Ther 95, no. 2 (February 2014): 141–46. https://doi.org/10.1038/clpt.2013.203.
Muir AJ, Gong L, Johnson SG, Lee MTM, Williams MS, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141–6.
Muir, A. J., et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.” Clin Pharmacol Ther, vol. 95, no. 2, Feb. 2014, pp. 141–46. Pubmed, doi:10.1038/clpt.2013.203.
Muir AJ, Gong L, Johnson SG, Lee MTM, Williams MS, Klein TE, Caudle KE, Nelson DR, Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141–146.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
February 2014
Volume
95
Issue
2
Start / End Page
141 / 146
Location
United States
Related Subject Headings
- Treatment Outcome
- Ribavirin
- Recombinant Proteins
- Polymorphism, Single Nucleotide
- Polyethylene Glycols
- Pharmacology & Pharmacy
- Interleukins
- Interferons
- Interferon-alpha
- Interferon alpha-2